References
- Traeger-Synodinos J, Harteveld CL. Advances in technologies for screening and diagnosis of hemoglobinopathies. Biomark Med. 2014;8(1):119–131
- Elion J, Wajcman H, Belkhodja-Dunda O, et al. Hemoglobin J Amiens β17(A14)Lys→Asn. Coincidence of a functionally silent new abnormal hemoglobin and a polycythemia vera. Nouv Rev Fr Hematol. 1979;21(4):347–352
- Harteveld CL, Voskamp A, Phylipsen M, et al. Nine unknown rearrangements in 16p13.3 and 11p15.4 causing α- and β-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet. 2005;42(12):922–931
- European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. EMA. 2012;44(5):1–28. (http://ema.europa.eu/docs/en_GB/document_library/Schientific_guideline/2012-06/WC500129256)
- Hardison RC, Chui DHK, Giardine B, et al. HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat. 2002;19(3):225–233 (http://globin.cse.psu.edu)
- Schnedl WJ, Lahousen T, Wallner SJ, et al. Silent hemoglobin variants and determination of Hb A1c with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem. 2005;38(1):88–91
- Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153–163
- Behan KJ, Storey NM, Lee HK. Reporting variant hemoglobins discovered during Hemoglobin A1c analysis – Common practices in clinical laboratories. Clin Chim Acta. 2009;406(1–2):124–128